These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2915904)

  • 1. Alternative 5' end of the bcr-abl transcript in chronic myelogenous leukemia.
    Romero P; Beran M; Shtalrid M; Andersson B; Talpaz M; Blick M
    Oncogene; 1989 Jan; 4(1):93-8. PubMed ID: 2915904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute lymphoid leukemia molecular phenotype in a patient with benign-phase chronic myelogenous leukemia.
    Guo JQ; Hirsch-Ginsberg CF; Xian YM; Stass SA; Champlin RE; Giralt SA; McCredie KB; Campbell ML; Arlinghaus RB
    Hematol Pathol; 1993; 7(2):91-106. PubMed ID: 8340287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24 homology domains but not the pleckstrin homology one.
    Martinelli G; Amabile M; Giannini B; Terragna C; Ottaviani E; Soverini S; Saglio G; Rosti G; Baccarani M
    Haematologica; 2002 Jul; 87(7):688-94; discussion 694. PubMed ID: 12091118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is p190 bcr-abl rearrangement necessary for acute transformation in some p210 CML of childhood?
    Scrideli CA; de Oliveira FM; Brassesco MS; de Paula Queiroz R; Bernardes JE; Valera ET; Tone LG
    Leuk Res; 2009 Mar; 33(3):495-9. PubMed ID: 18495245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
    Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G
    Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment and molecular characterization of a novel leukemic cell line with Philadelphia chromosome expressing p230 BCR/ABL fusion protein.
    Wada H; Mizutani S; Nishimura J; Usuki Y; Kohsaki M; Komai M; Kaneko H; Sakamoto S; Delia D; Kanamaru A
    Cancer Res; 1995 Jul; 55(14):3192-6. PubMed ID: 7606740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Molecular analysis of transformation into blast crisis in chronic myelogenous leukemia].
    Okabe M
    Hokkaido Igaku Zasshi; 1993 Mar; 68(2):237-50. PubMed ID: 8509066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alu and translisin recognition site sequences flanking translocation sites in a novel type of chimeric bcr-abl transcript suggest a possible general mechanism for bcr-abl breakpoints.
    Martinelli G; Terragna C; Amabile M; Montefusco V; Testoni N; Ottaviani E; de Vivo A; Mianulli A; Saglio G; Tura S
    Haematologica; 2000 Jan; 85(1):40-6. PubMed ID: 10629590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib.
    Agirre X; Román-Gómez J; Vázquez I; Jiménez-Velasco A; Larráyoz MJ; Lahortiga I; Andreu EJ; Márquez J; Beltrán de Heredia JM; Odero MD; Prósper F; Calasanz MJ
    Cancer Genet Cytogenet; 2005 Jul; 160(1):22-6. PubMed ID: 15949566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase.
    Beran M; Pisa P; O'Brien S; Kurzrock R; Siciliano M; Cork A; Andersson BS; Kohli V; Kantarjian H
    Cancer Res; 1993 Aug; 53(15):3603-10. PubMed ID: 8339266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
    Mahon FX; Ripoche J; Pigeonnier V; Jazwiec B; Pigneux A; Moreau JF; Reiffers J
    Exp Hematol; 1995 Dec; 23(14):1606-11. PubMed ID: 8542954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of bcr/abl gene in single hemopoietic progenitors in some patients with chronic myelogenous leukemia.
    Misawa M; Maeda H; Hara H; Yamamoto Y; Furuyama J
    Stem Cells; 1993 Nov; 11(6):536-42. PubMed ID: 7509222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic myelogenous leukemia with e13a3 (b2a3) type of BCR-ABL transcript having a DNA breakpoint between ABL exons a2 and a3.
    Liu LG; Tanaka H; Ito K; Kyo T; Ito T; Kimura A
    Am J Hematol; 2003 Dec; 74(4):268-72. PubMed ID: 14635208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABL-BCR mRNAs transcribed from chromosome 9q+ in Philadelphia-chromosome-positive chronic myeloid leukaemia.
    MacKenzie E; Stewart E; Birnie GD
    Leukemia; 1993 May; 7(5):702-6. PubMed ID: 8483322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two patients with novel BCR/ABL fusion transcripts (e8/a2 and e13/a2) resulting from translocation breakpoints within BCR exons.
    How GF; Lim LC; Kulkarni S; Tan LT; Tan P; Cross NC
    Br J Haematol; 1999 May; 105(2):434-6. PubMed ID: 10233416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Two Ph chromosome positive chronic myelogenous leukemia patients with rare bcr/abl fusion gene].
    Qin YZ; Liu YR; Li JL; Wang H; Chang Y; Fu JY; Ruan GR; Shi HL; Qiu JY; Lu DP; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2004 Jul; 25(7):409-12. PubMed ID: 15355693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of the BCR gene breakpoint and the type of BCR/ABL transcript to clinical course, prognostic indexes and survival in patients with chronic myeloid leukemia.
    Prejzner W
    Med Sci Monit; 2002 May; 8(5):BR193-7. PubMed ID: 12011769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional activation of human LIM-HOX gene, hLH-2, in chronic myelogenous leukemia is due to a cis-acting effect of Bcr-Abl.
    Wu HK; Minden MD
    Biochem Biophys Res Commun; 1997 Apr; 233(3):806-12. PubMed ID: 9168938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice.
    Casnici C; Volpe G; Lattuada D; Crotta K; Kuka M; Panuzzo C; Mastrotto C; Tonon G; Fazio VM; Saglio G; Marelli O
    Cancer Lett; 2009 Apr; 276(1):61-7. PubMed ID: 19062160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fusion of the bcr and the c-abl genes in Ph'-positive acute lymphocytic leukemia with no rearrangement in the breakpoint cluster region.
    ar-Rushdi A; Negrini M; Kurzrock R; Huebner K; Croce CM
    Oncogene; 1988 Apr; 2(4):353-7. PubMed ID: 3283653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.